Is it $360mn peak revenues? I thought that was milestone payments. Royalties as a % of sales would be uncapped, right?
Also, I don’t think 2030 would be the peak. Unlike a cancer treatment where drug use stops once recovery is completed, we are told FSGS is chronic, ie lifelong disease and hence lifelong revenues. So with higher adoption the revenues should keep increasing over time. So I don’t think 2030 will be the peak unless a different drug cannibalises the market.
Obviously diabetic kidney disease etc are cherries on top to come later but I expect that the trials will start soon and it will again add huge TAM. The question is when is our buyout?
AIMO. DYOR.
Is it $360mn peak revenues? I thought that was milestone...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
-0.035(7.22%) |
Mkt cap ! $247.5M | |||
| Open | High | Low | Value | Volume |
| 48.5¢ | 48.5¢ | 44.5¢ | $1.897M | 4.104M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 79166 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 103477 | 2 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |